The global pulmonary edema therapeutics market size was valued at USD 150 million in 2021 and is projected to reach around USD 550 million in 2030 exhibiting a CAGR of 4.5% in the forecasted period. The rising incidence of heart failure, a major cause of pulmonary edema, an increasing geriatric population, and growing awareness about pulmonary edema are some of the key factors anticipated to drive the market. On the other hand, risks associated with heart treatments and side effects of the treatment are anticipated to hinder the growth of pulmonary edema therapeutics market growth.
The global market for pulmonary edema therapeutics will expand owing to the growing incidence of heart failure, a major cause of pulmonary edema. For example, as per the Places for Infectious prevention and Anticipation, in 2020, about 6.2 million grown-ups in the U.S. had a cardiovascular failure. Moreover, pulmonary edema is a disorder caused by extra fluids in the lungs. The fluids gather in the various air sacs in the lungs making it problematic to breathe. Furthermore, according to the National Heart, Lung and Blood Institute Atherosclerotic Risk in Communities (ARIC) study and Cardiovascular Health Study(CHS) there are around 1,260,000 new and recurrent coronary attacks per year- around 37% people experience coronary attack in a given year die from it. Additionally, the use of intra-ventricular septum contributing to the pumping function of left ventricle, lung parenchyma leading to lung diseases, upsurge in hypertensive crisis, pulmonary shunt and the use of arterial blood gas to measure the quantity of arterial gases such as oxygen and carbon dioxide is additionally driving its market growth.
The pulmonary edema therapeutics market and healthcare systems have been reasonably affected by the COVID-19 pandemic. Irregular alveolar fluid metabolism in the lungs, which causes fluid build-up in the alveolar airspace, is the major cause of COVID-19 mortality. Contamination with the severe acute respiratory syndrome coronavirus is the cause of this condition, which is called as pulmonary edema. Recognizing the pathways that may add to pulmonary edema in people with severe Coronavirus Disease (COVID-19) may help in the treatment of this situation.
Type Insights
Based on the type, the market is categorized into cardiogenic pulmonary edema and non-cardiogenic pulmonary edema. Out of these, cardiogenic pulmonary edema to hold an important share of the market in 2021. This is typically due to the growing rate of heart failure as it is one of the most common reasons of cardiogenic pulmonary edema and it is one of the most common grounds of death between adults worldwide.
Distribution Channel Insights
On the basis of distribution channel, the pulmonary edema therapeutics market has been categorized into retail pharmacies, hospital pharmacies, and online pharmacies. The hospital pharmacies category is to observe higher adoption of pulmonary edema therapeutics during the forecasted period. This is mostly owing to the accessibility of experienced healthcare professionals & the safety & efficiency throughout the treatment procedures also increasing hospital administration of pulmonary edema patients globally are the major aspects for the growth of the segment.
Region Insights
North America is projected to grow at a substantial CAGR during the forecasted period. The high prevalence of risk factors and the increasing acceptance of medications to treat pulmonary edema are factors for the growth of the market in the region. Additionally, the region's plenty of clinics and accessibility to scientifically advanced instruments are additionally driving the market's expansion. Moreover, the Centers for Disease Control and Prevention estimate that heart disease accounts for 647,000 annual deaths in the US, or 1 in 4 deaths.
Key Companies Insights
The market for Pulmonary edema therapeutics is moderately competitive. With the rising applications of Pulmonary edema therapeutics, new players are considering to enter the market. The companies are also involved in events like joint ventures, acquisitions, partnerships, mergers, and collaborations. These activities aid in growing the effect of the players in the Pulmonary edema therapeutics market, ultimately boosting the market growth. Some of the key companies working in the global Pulmonary edema therapeutics market include:
• AbbVie Inc.
• ADVANZ PHARMA Corp.
• Apotex Inc.
• Bausch Health Companies Inc.
• CHIESI Farmaceutici SpA
• CMP Pharma Inc.
• Johnson and Johnson
• Lupin Ltd.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd.
• Validus Pharmaceuticals LLC
• Other players
Some of the Recent Developments:
• In February 2022, AstraZeneca is sticking out with an animated fantasyland theme for its Breztri TV ad but uses a blast from the past to demonstrate a brighter future. The primary phase requests patients to "Get Real" about their chronic obstructive pulmonary disease (COPD) and flare-ups, highlighting that improved breathing doesn't make everything "fun and nice."
• In January 2022, MediPines Corporation announced for complete national distribution throughout the United States for its exclusive AGM100device, first FDA-cleared, non-invasive pulmonary gas exchange analyzer system across the globe.
• In April 2020, Altimmune collaborated with University of Birmingham moving a single dose nasal vaccine AdCovid into clinical trials.
Segments
By Type
• Cardiogenic pulmonary edema
• Non-cardiogenic pulmonary edema
By Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
By Geography
• North America
o U.S.
o Canada
o Mexico
• Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Russia
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o ASEAN
• Latin America
o Brazil
o Argentina
o Colombia
• MEA
o South Africa
o Saudi Arabia
o UAE
o Egypt